A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
Status:
COMPLETED
Trial end date:
2025-02-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of intravenously administered VX-993 at different doses in healthy participants.